Towards an optimal interval for prostate cancer screening

European Urology

Volumn 61, Issue 1, 2012, Pages 171-176

  Van Leeuwen, Pim J ^a   Roobol, Monique J ^a   Kranse, Ries ^b   Zappa, Marco ^c   Carlsson, Sigrid ^d   Bul, Meelan ^a   Zhu, Xiaoye ^a   Bangma, Chris H ^a   Schröder, Fritz H ^a   Hugosson, Jonas ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Dutch Cancer Registry (IKNL)   (Netherlands)

^c INSTITUTE FOR THE STUDY AND PREVENTION OF CANCER   (Italy)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Early detection; Interval; Prostate cancer; PSA; Screening

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER; TIME;

BIOPSY; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 82255191762     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.002     Document Type: Article

References (19)

1. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
2. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
3. M.J. Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
4. R. Taylor, A. Page, D. Bampton, J. Estoesta, and M. Rickard Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years J Med Screen 11 2004 199 206 (Pubitemid 40006744)
5. R. Taylor, R. Supramaniam, M. Rickard, J. Estoesta, and C. Moreira Interval breast cancers in New South Wales, Australia, and comparisons with trials and other mammographic screening programmes J Med Screen 9 2002 20 25 (Pubitemid 34327138)
6. N.E. Day, D.R. Williams, and K.T. Khaw Breast cancer screening programmes: the development of a monitoring and evaluation system Br J Cancer 59 1989 954 958 (Pubitemid 19155717)
7. I.W. van der Cruijsen-Koeter, T.H. van der Kwast, and F.H. Schroder Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam J Natl Cancer Inst 95 2003 1462 1466 (Pubitemid 37279331)
8. M.J. Roobol, A. Grenabo, F.H. Schroder, and J. Hugosson Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam J Natl Cancer Inst 99 2007 1296 1303 (Pubitemid 47398681)
9. J.L. Bulliard, P. Sasieni, C. Klabunde, J.P. De Landtsheer, B.C. Yankaskas, and J. Fracheboud Methodological issues in international comparison of interval breast cancers Int J Cancer 119 2006 1158 1163 (Pubitemid 44116926)
10. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
11. F. Bray, R. Sankila, J. Ferlay, and D.M. Parkin Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38 2002 99 166 (Pubitemid 34031832)
12. Breslow NE DN. Statistical methods in cancer research 1987 IARC Scientific Publications Lyon, France
13. M.J. Roobol, F.H. Schröder, and E.D. Crawford A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120
14. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
15. H.B. Carter, J.I. Epstein, D.W. Chan, J.L. Fozard, and J.D. Pearson Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer JAMA 277 1997 1456 1460 (Pubitemid 27208888)
16. K. Ito, T. Yamamoto, and M. Ohi Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less Prostate 57 2003 8 13 (Pubitemid 37070144)
17. M.J. Roobol, D.W. Roobol, and F.H. Schroder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
18. P.J. van Leeuwen, D. Connolly, and T.L. Tammela Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865
19. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521